{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:46:28Z","timestamp":1758991588522},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1303,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p>The haemophilias are a group of inherited haemostatic disorders that require regular clotting factor replacement therapy in the severe and moderately severe subgroups. Prior to the introduction of adequate viral inactivation methods in 1985, haemophilia patients were at exceptionally high risk of contracting blood\u2010borne viruses from factor concentrates as each batch was derived from the plasma of thousands of donors. As a result, approximately 60% of these patients were infected with HIV between 1979 and 1985, and HIV infection now contributes significantly to the morbidity and mortality seen in this group.<\/jats:p><jats:p>Protease inhibitors (PIs) have been shown to significantly log reduce viral loads and increase CD4 cell counts in HIV\u2010infected individuals. Recently, there has been concern about their use in HIV\u2010infected haemophilia patients following increased bleeding episodes in some patients during PI therapy. We prospectively studied the effect of PI therapy in 20 HIV\u2010infected haemophilia patients at our centre over a 6\u2010month period. The mean increase in CD4 cell count was 70\u2003\u00d7\u200310<jats:sup>6<\/jats:sup>\/l and the mean log decrease in viral load was 1.59 over the study period. Gastrointestinal side\u2010effects (nausea and vomiting in five, diarrhoea in two) were the most frequent and resulted in discontinuation of the medication in two patients. Factor concentrate usage for the group on and off study was similar. One severe FVIII patient reported a single episode of an unusual bleed which responded promptly to FVIII concentrate infusion. The significant clinical and laboratory benefits in terms of HIV disease and the paucity of added bleeding complications suggest that PI therapy should not be withheld from HIV\u2010infected haemophilics. Further prospective studies evaluating the efficacy and possible haemostatic complications related to these promising inhibitors of the HIV protease are needed.<\/jats:p>","DOI":"10.1046\/j.1365-2141.1998.00734.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:01:49Z","timestamp":1047362509000},"page":"475-479","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Successful use of protease inhibitors in HIV\u2010infected haemophilia patients"],"prefix":"10.1111","volume":"101","author":[{"given":"Concepta","family":"Merry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrina","family":"Mcmahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairin","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"O'shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1199","article-title":"Monitoring but no drug regimen change advised for hemophiliac patients taking protease inhibitors","volume":"53","author":"Anon.","year":"1996","journal-title":"American Journal of Health Systems Pharmacology"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732030-00003"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb01173.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)12073-0"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1997.03540480062040","article-title":"Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society; U.S.A. Panel","volume":"277","author":"Carpenter C.C.J.","year":"1997","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604183341602"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1992.8.153"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1990.tb00846.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00644.x"},{"key":"e_1_2_5_11_2","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multi\u2010transfused hemophiliacs: effect of coinfection with human immunodeficiency. The Multi\u2010center Haemophilia Cohort Study","volume":"6","author":"Eyster M.","year":"1993","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"e_1_2_5_12_2","unstructured":"F.D.A.(1996) HIV protease inhibitors and patients with hemophilia. Letter to health care providers. FDA July 1996."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)22020-9"},{"key":"e_1_2_5_14_2","first-page":"256","article-title":"Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small\u2010intestinal cytochrome P4503A4","volume":"25","author":"Fitzsimmons M.E.","year":"1997","journal-title":"Drug Metabolism and Disposal"},{"key":"e_1_2_5_15_2","first-page":"388","article-title":"Unusual occurrence of spontaneous haematomas in three asymptomatic HIV infected patients a few days after the onset of ritonavir treatment","volume":"11","author":"Ginsburg C.","year":"1997","journal-title":"AIDS"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/373123a0"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07353.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90959-1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of HIV\u20101 protease to treat HIV\u20101 infection","volume":"333","author":"Markowitz M.","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.5.2.155"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804143181503"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199652010-00007"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196512302732701"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-625"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92828-X"},{"key":"e_1_2_5_27_2","first-page":"2","article-title":"HIV protease inhibitors and increased bleeding in haemophilia","volume":"1","author":"WHO Newsletter","year":"1997","journal-title":"WHO ADR Newsletter"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.t01-1-00098.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00734.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00734.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2141.1998.00734.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00734.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:16:15Z","timestamp":1694416575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.1998.00734.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2141.1998.00734.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00734.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]},"assertion":[{"value":"2001-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}